DBV Technologies S.A.

DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq

2026-07-30 17:40:00

Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that, pursuant to the Company's At-The-Market Program established on September 1, 2025 and included in a new registration statement and accompanying prospectus filed on July 27, 2026, (the “ATM Program”), it has agreed to issue and sell new ordinary shares (the “Ordinary Shares”) in the form of American Depositary Shares (“ADSs”), for total gross proceeds to the Company of approximately $50 million, before deducting sales agent commissions and offering expenses payable by the Company, to RA Capital Management, L.P (“RA Capital”) through Citizens JMP Securities, LLC (“Citizens”), acting as sales agent. Each ADS represents the right to receive five Ordinary Shares of the Company.

DBV Technologies: Regulatory Noise, Commercial Misperception, And A Deep Valuation Gap

2026-07-26 08:23:31

DBV Technologies is rated Buy following positive Phase 3 VITESSE results. My risk- and dilution-adjusted DCF yields $42 per ADS, more than double the current share price. The model assumes that 60% of diagnosed children with adequate insurance coverage ultimately initiate treatment, reflecting Viaskin's favorable safety profile, user-friendly administration, and the significant burden of avoidance-only management. An initial backlog of untreated children creates a temporary annual revenue peak above $1.6bn before revenues stabilize around $1bn as the market reaches steady state.

DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside

2026-07-23 16:46:43

DBV Technologies is rated a buy, with a 24% upside to a $17 FY 2027 price target as Viaskin nears BLA submission. DBVT's transition from research to commercial readiness is evident, with rising sales/marketing spend and declining research tax credits signaling operational progress. The key catalyst is the planned Q3 2026 BLA submission, expected to trigger a 10-month FDA review and potential commercial launch in 2027.

DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales

2026-07-17 17:00:00

Châtillon, France, July 17, 2026 DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that it has filed a new automatically effective shelf registration statement on Form S-3ASR (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”), which includes a base prospectus and a sales agreement prospectus supplement refreshing the Company's previously established at-the-market offering program (the “ATM Program”) by filing a prospectus supplement for sales of up to $150 million of American Depositary Shares (“ADS”). The ATM Program was established pursuant to a sales agreement dated September 5, 2025, (the “Sales Agreement”) with Citizens JMP Securities, LLC (“Citizens”), acting as sales agent, under which the Company may offer and sell, from time to time, ADSs, each ADS representing five ordinary shares of the Company, having an aggregate offering price of up to $150 million, subject to French regulatory limits.

DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript

2026-07-16 19:26:16

DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript

DBV Technologies Q2 Earnings Call Highlights

2026-07-16 19:03:42

DBV Technologies NASDAQ: DBVT said it is continuing preparations for a planned third-quarter 2026 Biologics License Application submission for its VIASKIN Peanut Patch in children ages 4 through 7, while also building commercial infrastructure ahead of a potential U.S. launch.

DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report

2026-07-16 16:10:00

Châtillon, France, July 16, 2026 DBV Te c hnologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the semester ended June 30, 2026, of its Half-Year Report with the French market authority, “Autorité des Marchés Financiers” (“AMF”). The 2026 Half-Year Report can be consulted or downloaded from the Company's website (www.dbv-technologies.com) in the section Investors/Financial Information, and on the AMF website (www.amf-france.org), in French only.

DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update

2026-07-16 16:01:00

Châtillon, France, July 16, 2026 DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update Continued productive engagement with the FDA in support of the BLA for the VIASKIN® Peanut Patch in children aged 4 through 7 years, with submission of the BLA anticipated in the third quarter of 2026 Reported cash and cash equivalents of $174.9 million as of June 30, 2026, funding into third quarter of 2027 DBV will host a conference call today, July 16, at 5:00pm ET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a late-stage biopharmaceutical company, today reported financial results for the Second Quarter and Half-Year of 2026. The quarterly and Half-Year financial statements were approved by the Board of Directors on July 16, 2026.